SCHEMBL8488000

SCHEMBL8488000

O=C(NC[C@H](NC(=O)c1cccc(O)c1O)C(=O)O)c1cccc(O)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.54
TERT O14746 2/20 0.46
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
TAAR1 Q96RJ0 1/20 0.40
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NLRP1 Q9C000 1/20 0.39
ITGAV P06756 3/20 0.39
ITGB1 P05556 2/20 0.39
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39
HPGDS O60760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8487702 1.00 ALOX5 (0.54) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL8487602 0.87 ALOX5 (0.53) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL8488358 0.87 ALOX5 (0.53) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL8489543 0.87 ALOX5 (0.53) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL7669752 0.85 ALOX5 (0.59) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL407186 0.84 CA2 (0.50) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL11247265 0.84 CA2 (0.50) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL407185 0.84 CA2 (0.50) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL8488598 0.84 ALOX5 (0.50) ALOX5TERTKDM4EALDH1A1HPGD
SCHEMBL8487220 0.84 ALOX5 (0.50) ALOX5TERTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999042435-A2 MYXOCHELINES ANALYTICON AG BIOTECHNOLOGIE PHARMAZIE (DE) 1999-08-26 WO claimed
US-20190352691-A1 PATHOGEN DETECTION UNIVERSITY OF NOTRE DAME DU LAC (US) 2019-11-21 US disclosed
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160319322-A1 PATHOGEN DETECTION UNIVERSITY OF NOTRE DAME DU LAC (US) 2016-11-03 US disclosed
WO-1999042435-A2 MYXOCHELINES ANALYTICON AG BIOTECHNOLOGIE PHARMAZIE (DE) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS HAMP, SLC40A1, FTH1 ALOX5 3013/4885TERT 4758/4885KDM4E 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.